Joshua Resnick has left MRL Ventures Fund, a corporate venturing subsidiary of pharmaceutical firm Merck to join US-based venture capital firm SV Life Sciences as a partner.
Resnick served as president and managing partner of MRL Ventures, which acts as Merck’s early-stage biotherapeutics investment unit, from December 2014. He is on the board of directors at MRL portfolio companies Spero Therapeutics, RaNA Therapeutics, Miragen and Visterra.
Prior to Merck, Resnick was a venture partner at VC firm Atlas Venture, after serving as a partner at another VC firm, Prism Venture Works, for seven years from 2005. He will join SV’s biotech investment team.
– Photo of Joshua Resnick courtesy of LinkedIn